Emergent Biosolutions Total Liab Over Time
| EBS Stock | USD 9.48 0.08 0.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Emergent Biosolutions Performance and Emergent Biosolutions Correlation. Emergent |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.022 | Earnings Share (11.22) | Revenue Per Share 21.448 | Quarterly Revenue Growth 0.086 | Return On Assets (0.04) |
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine if Emergent Biosolutions is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare Emergent Biosolutions and related stocks such as Zoetis Inc, PetIQ Inc, and Bausch Health Companies Total Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZTS | 1.9 B | 2 B | 2.2 B | 5.6 B | 5.3 B | 6.8 B | 6.2 B | 6.8 B | 8.6 B | 8.8 B | 9.8 B | 9.4 B | 10.5 B | 9.3 B | 7.3 B |
| BHC | 25.9 M | 9.1 B | 14.2 B | 22.7 B | 20.9 B | 42.9 B | 40.3 B | 31.6 B | 24.6 B | 32.7 B | 30.6 B | 29.2 B | 25.4 B | 27.4 B | 28.8 B |
| NBIX | 5.2 M | 78.3 M | 41.6 M | 34.3 M | 34.3 M | 50.3 M | 50.2 M | 445.5 M | 512.4 M | 669.1 M | 608.5 M | 698.5 M | 660.9 M | 1 B | 1.1 B |
| AKAN | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 10.2 M | 12.1 M | 12.7 M | 12.2 M |
| LFCR | 1.8 M | 126.1 M | 110.5 M | 108.9 M | 126.4 M | 131.1 M | 129.9 M | 152.1 M | 248.9 M | 310.3 M | 300.1 M | 187.2 M | 187.3 M | 219.8 M | 110.9 M |
| PBH | 105.3 M | 1.4 B | 1.3 B | 1.2 B | 2 B | 2.2 B | 3.1 B | 2.6 B | 2.3 B | 2.3 B | 2.1 B | 2.1 B | 1.9 B | 1.7 B | 1.4 B |
| ITCI | 5.7 M | 5.7 M | 2.8 M | 6.8 M | 10.6 M | 7.9 M | 13.4 M | 17 M | 39.5 M | 56.2 M | 60.5 M | 72 M | 98.7 M | 136.9 M | 143.7 M |
| ALKS | 1.5 M | 581.4 M | 517.9 M | 512.4 M | 524.4 M | 541.5 M | 516.9 M | 594.4 M | 653.7 M | 720 M | 882.7 M | 911.9 M | 920.2 M | 933.5 M | 980.2 M |
| CPIX | 3.9 M | 12.7 M | 13 M | 8.3 M | 14.7 M | 15.1 M | 20.3 M | 29.3 M | 57.1 M | 53.5 M | 49.6 M | 41.9 M | 57 M | 52.5 M | 29.9 M |
| COLL | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 17.3 M | 12.6 M | 27.1 M | 31.5 M | 199.7 M | 218.9 M | 457.8 M | 489.1 M | 979.3 M | 947.9 M | 995.3 M |
| DRRX | 1.7 M | 45.7 M | 9.6 M | 10.1 M | 31.6 M | 31.9 M | 32.2 M | 31.6 M | 30 M | 63.2 M | 35.5 M | 34.2 M | 35.1 M | 30.4 M | 39.1 M |
Emergent Biosolutions and related stocks such as Zoetis Inc, PetIQ Inc, and Bausch Health Companies Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| Emergent Biosolutions | EBS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Maryland; U.S.A |
| Exchange | New York Stock Exchange |
USD 9.48
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.